Skip to main content

Table 2 .

From: Comparison of adverse events in partial- or whole breast radiotherapy: investigation of cosmesis, toxicities and quality of life in a meta-analysis of randomized trials

Trial

Additional publications

Cosmetic evaluation

Quality of Life

Any acute

Acute skin

Acute lung

Acute breast pain

Any late

Late skin

Late subcutaneous/tissue

Late telangiectasia

Late breast edema

Late breast pain

Late chest- wall pain

Late Fat Necrosis

Late lung

NSABP B-39

Vicini 2019 [98]

White 2019 [25]

Vicini 2019 [50]

4p GCS: 3y (MP) [25]

4p GCS: 3y (Pat) [25]

BCTOS, Pain Score, SF-36 [99]

n.r

n.r

n.r

n.r

n.r

n.r

n.r

n.r

n.r

n.r

n.r

n.r

n.r

Budapest

Polgar 2004 [100]

Polgar 2007 [101]

Lövey 2007 [102]

Polgar 2013 [103]

Polgar 2014 [104]

Polgar 2020 [27]

4p: 5y, 10y, 20y (MP) [27, 101, 104]

n.r

n.r

n.r

n.r

n.r

RTOG/EORTC

G3 +  [104]

RTOG/EORTC G1 + ,G2 + ,G3 +  [27]

RTOG/EORTC

G1 + ,G2 + ,G3 +  [27]

RTOG/EORTC G3 +  [104]

n.r

n.r

n.r

G1 + ,G2 + ,G3 + ,G4 +  [102]

n.r

RAPID

Olivotto 2013 [105]

Peterson 2015 [53]

Whelan 2019 [106]

Whelan 2019 [26]

4p: 3y,5y,7y (Nurse) [26]

4p: 3y,5y,7y (Pat) [26]

n.r

CTCAE V3: G2 + ,G3 +  [26]

CTCAE V3: G2 + ,G3 +  [26]

CTCAE V3: G2 + ,G3 +  [26]

CTCAE V3: G2 + ,G3 +  [26]

CTCAE V3: G2 + ,G3 +  [26]

n.r

CTCAE V3: G2 + ,G3 +  [26]

CTCAE V3: G2 + ,G3 +  [26]

n.r

CTCAE V3: G2 + ,G3 +  [26]

CTCAE V3: G2 + ,G3 +  [26]

CTCAE V3: G2 + ,G3 +  [26]

n.r

IRMA

Meduri 2017 [33]

Meduri 2020 [107]

Meduri 2023 [108]

4p: 1y,3y,5y (MP) [107]

4p: 1y,3y,5y (Pat) [107]

n.r

n.r

RTOG/EORTC G1 + ,G2 + ,G3 +  [107, 108]

n.r

n.r

n.r

RTOG/EORTC

G1 + ,G2 + ,G3 +  [107, 108]

RTOG/EORTC G1 + ,G2 + ,G3 +  [107, 108]

n.r

n.r

n.r

RTOG/EORTC Bone G1 + ,G2 + ,G3 +  [107]

n.r

RTOG/EORTC

G1 + ,G2 + ,G3 +  [107]

Barcelona

Rodriguez 2013 [30]

Li 2021 [109]

4p: 1y,3y,5y,10y (MP) [30, 109]

n.r

 

RTOG/EORTC

G1 + ,G2 + .G3 +  [30]

RTOG/EORTC G2 +  [30]

n.r

RTOG/EORTC

G1 +  [109]

RTOG/EORTC

G1 +  [109]

RTOG/EORTC G1 + , G2 +  [109]

n.r

n.r

RTOG/EORTC

G1 +  [109]

n.r

n.r

n.r

India

Yadav 2019 [51]

4p: 5y (MP) [51]

n.r

n.r

RTOG/EORTC

G1 + ,G2 + ,G3 +  [51]

n.r

n.r

RTOG/EORTC

G3 +  [51]

RTOG/EORTC

G3 +  [51]

RTOG/EORTC induration

G1 + ,G2 +  [51]

n.r

RTOG/EORTC

G1 + ,G2 +  [51]

n.r

n.r

RTOG/EORTC

G1 +  [51]

n.r

Cairo

Boutrus 2018 [24]

4p: 6 m,1y [24]

n.r

 

RTOG/EORTC

G3 +  [24]

RTOG/EORTC G1 +  [24]

n.r

n.r

RTOG/EORTC

G3 +  [24]

RTOG/EORTC G3 +  [24]

RTOG/EORTC G1 +  [24]

n.r

n.r

n.r

n.r

n.r

Florence

Livi 2010 [77]

Livi 2015 [110]

Meattini 2017 [111]

Meattini 2020 [112]

Meattini 2020 [32]

4p: 5y,10y (MP) [32, 110]

4p: 5y,10y (Pat) [32, 110]

EORTC QLQ-C30 [111]

EORTC QLQ-BR23 [111]

RTOG/EORTC:

G1 + ,G2 + ,G3 +  [32]

RTOG/EORTC: G1 + ,G2 + ,G3 +  [112]

n.r

n.r

RTOG/EORTC:

G1 + ,G2 +  [32]

RTOG/EORTC:

G1 + ,G2 +  [112]

n.r

n.r

n.r

n.r

n.r

n.r

n.r

Import low

Coles 2017 [35]

Bhattacharya 2019 [52]

Bhattacharya 2019 [113]

Bhattacharya 2019 [114]

3p PA: 2y,5y (MP) [35]

4p: 5y (Pat: Breast appearance changed) [35]

4p dich. EORTC QLQ-C30 [35]

4p dich. EORTC QLQ-BR23 [35]

n.r

n.r

n.r

n.r

4p “Worst normal-tissue effect” [35] Different scale

4p “Skin problems in breast” (Pat) [35] Different scale

4p breast induration (index) [35] Different scale

4p teleangiectasia [35] Different scale

4p breast edema [35]

Different scale

4p breast pain (pain) [35]

Different scale

Symptomatic rib fracture reported [35]

different scale

n.r

Symptomatic lung fibrosis reported [35]

different scale

DBCG PBI

Offersen 2017 [29]

Offersen 2022 [36]

4p GCS: 3y 5y (MP)

4p: 3y 5y (Pat satisfaction) [29, 36]

n.r

n.r

n.r

n.r

n.r

n.r

Scar appearance G2 +  [36]

4p Breast Induration G2 +  [36]

4p teleangiectasia

G2 +  [36]

4p edema G2 +  [36]

4p pain G2 +  [36]

n.r

n.r

n.r

HYPAB

Franceschini 2020 [115]

4p GCS: 6 m (MP) [115]

n.r

CTCAE V4: G1 + , G2 + , G3 +  [115]

CTCAE V4 G1 + , G2 + , G3 +  [115]

n.r

n.r

CTCAE V4:

G1 + , G2 + , G3 +  [115]

n.r

n.r

n.r

n.r

n.r

n.r

CTCAE V4 G3 +  [115]

 

Beijing

Song 2021 [116]

n.r

EORTC QLQ-C30 [116]

EORTC QLQ-BR23 [116]

n.r

n.r

n.r

n.r

n.r

n.r

n.r

n.r

n.r

n.r

n.r

n.r

 

ELIOT

Veronesi 2013 [31]

Orecchia 2021 [117]

n.r

n.r

n.r

LENT SOMA G1 + ,G3 + ,G4 +  [31]

n.r

n.r

n.r

LENT SOMA G1 +  [31]

n.r

n.r

n.r

n.r

n.r

LENT SOMA G1 +  [31]

LENT SOMA G1 + ,G2 + ,G3 +  [31]

TARGIT-A

prepathology

Vaidya 2010 [118]

Andersen 2012 [119]

Sperk 2012 [120]

Welzel 2013 [60]

Keshtgar 2013 [121]

Vaidya 2014 [122]

Vaidya 2016 [123]

Corica 2016 [124]

Corica 2018 [34]

Vaidya 2020 [125]

Vaidya 2020 [126]

4p: 1y,2y,3y,4y,5y (Nurse) [34]

4p: 1y,2y,3y,4y,5y (Pat) [34]

EORTC QLQ-C30 [60, 124]

EORTC QLQ-BR23 [60, 124]

RTOG G3 +  [123]

RTOG G3 +  [123]

n.r

n.r

n.r

RTOG/EORTC G3 +  [123]

LENT SOMA G2 + ,G3 + Cum inc (3y) [120]

LENT SOMA G1 + Cum inc (3y) [120]

LENT SOMA G2 +  [120]

Any breast pain G1 +  [119] LENT SOMA G2 + Cum inc (3y) [120]- Different scales

n.r

n.r

n.r

TARGIT-A

postpathology

                

GEC ESTRO

Ott 2016 [127]

Strnad 2016 [128]

Polgar 2017 [129]

Schäfer 2018 [28]

Strnad 2023 [130]

4p: 1y,3y,5y (MP) [129]

4p: 1y,3y,5y (Pat) [129]

EORTC QLQ-C30 [28]

EORTC QLQ-BR23 [28]

CTCAE V3 G3 +  [127]

CTCAE V3 G1 + ,G2 + ,G3 +  [127]

n.r

CTCAE V3 G1 + ,G2 +  [127]

RTOG/EORTC

G1 + ,G3 +  [130]

RTOG/EORTC Skin G1 + ,G2 + ,G3 +  [129, 130]

RTOG/EORTC subcutaneous tissue G1 + ,G2 + ,G3 +  [129, 130]

LENT SOMA teleangiectasia

G1 + ,G2 + ,G3 +  [129, 130]

n.r

LENT SOMA pain G1 + ,G2 + ,G3 +  [129]

n.r

LENT SOMA fat necrosis

G1 + ,G2 + ,G3 +  [129]

n.r